Trilantic North America Completes Strategic Growth Investment in SOFIE Biosciences
NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity […]
Focus on FAPI Newsletter – Q2 2024
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review GalleryThe Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review
The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review
Domenico Albano, Alessio Rizzo, Riemer H J A Slart, Søren Hess, Edel Noriega-Álvarez, Cristina Gamila […]
Current State of FAP Targeting Radioligands
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
May 30, 2024 Download the Presentation […]
Current State of FAP Targeting Radioligands
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
2024 Annual SNMMI Meeting – Toronto, Canada
May […]
[18F]FAPI-74 serving as complementary diagnostic in Avacta Phase 1 trial
May 23, 2024 – SOFIE is pleased to partner with Avacta through Avacta’s use […]
![[68Ga]Ga-FAPI-46 PET/CT for penile cancer - a feasibility study](https://sofie.com/wp-content/uploads/2024/06/info.ibamolecular.png)
[68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study
Lennert Eismann, Stephan T Ledderose, Benazir Enzinger, Elena Berg, Thilo Westhofen, Severin Rodler, Gerald B […]
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy Gallery68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas […]
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers
Marinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, Thierry N Boellaard, Francesco Sanguedolce, Daniela […]
Highlights of the 36th EANM Annual Congress 2023, from hometown Vienna, Austria: “A SYMPHONY OF SCIENCE”
David Kersting, Silvia Morbelli, Sophie E. M. Veldhuijzen van Zanten & Hein J. Verberne